Category Archives: Genetic Therapy

Roots Analysis has done a detailed study on Gene Therapy Market (3rd Edition), 2019-2030, covering key aspects of the industrys evolution and identifying potential future growth opportunities.

Key Market Insights

For more information, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html

Table of Contents

4.2.1 Types of Viral Vectors

11.2 Analysis by Special Designations Awarded

11.3.1. Analysis by Target Indication

11.3.2. Analysis by Type of Vector Used

11.4.1. Analysis by Target Indication

11.4.2. Analysis by Type of Vector Used

11.5.1. Analysis by Target Indication

11.5.2. Analysis by Type of Vector Used

11.6.1. Analysis by Target Indication

11.6.2. Analysis by Type of Vector Used

11.7.1. Analysis by Target Indication

11.7.2. Analysis by Type of Vector Used

11.8.1. Analysis by Target Indication

11.8.2. Analysis by Type of Vector Used

11.9.1. Analysis by Target Indication

11.9.2. Analysis by Type of Vector Used

11.10.1. Analysis by Target Indication

11.10.2. Analysis by Type of Vector Used

11.11.1. Analysis by Target Indication

11.11.2. Analysis by Type of Vector Used

11.12.1. Analysis by Target Indication

11.12.2. Analysis by Type of Vector Used

11.13.1. Analysis by Target Indication

11.13.2. Analysis by Type of Vector Used

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If youd like help with your growing business needs, get in touch at [emailprotected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[emailprotected]

See more here:
The Gene Therapy Market is projected to grow at an annualized rate of 45%, till 2030 - Scientect

TipRanks

One thing is for sure, 2020 threw the world into a tailspin. The spread of COVID-19 devastated the economy, and took investors on a rollercoaster ride that featured massive amounts of volatility packed into a span of only a few months. Investors saw stocks take a fast and frightening nose dive, only to be followed up by a fierce V-shaped rebound. Against this backdrop, U.S. 10-year and 30-year bond yields plummeted to all-time lows and unemployment levels clocked in at alarming highs. Still, despite all of the chaos, a select few retail names have stolen the show, delivering applause-worthy performances. With this in mind, we used TipRanks database to identify three retail stocks that have earned a Strong Buy consensus rating from the analyst community. Let's take a look. Carters (CRI) First in line is Carter's, a company whose name is synonymous with childrenswear. The companys brands include Carter's, OshKosh, Skip Hop, Child of Mine, to name a few, and it operates three segments: U.S. Retail (1,100 retail stores), U.S. Wholesale (18,000 locations) and International. Carters second quarter operating results were negatively impacted by the COVID-19 pandemic. Retail stores were closed for much of the quarter and sales to wholesale customers declined. Overall, sales fell 29.9% to $219.5 million, while adjusted earnings per share dropped 43% to $0.54. A bright spot in the quarter was online sales, which jumped an impressive 101%. Despite the poor quarter and lingering effects of COVID-19, B.Riley FBR analyst Susan Anderson, believes the company is well positioned, pointing out the name has rebounded 24% since March 23. The bright spot is that CRI is not exposed as much to BTS (back to school) relative to competitors and 50% of sales come from the baby category, which is not impacted by an anticipated weaker BTS season, she commented. On top of that, the B.Riley FBR analyst considers Carters to be the best of the bunch, stating, we continue to believe CRI is the premier children's apparel retailer and manufacturer that will be able to come out of the COVID-19 pandemic on stronger footing as other children's retailers struggle. Anderson rates the stock a Buy, writing, CRI's high e-commerce penetration, growth initiatives, and cost-reduction measures make CRI a strong buy. She has a $103 price target on the stock, which adds up to a potential rise of 27% from the current share price. (To watch Andersons track record, click here) Similarly, most of the Street is on board. 3 Buys and only 1 Hold assigned in the last three months add up to a Strong Buy analyst consensus. In addition, the $101.25 average price target puts the potential upside at 25%. (See Carters stock analysis on TipRanks) Callaway Golf Company (ELY) Next in line is Callaway Golf Company, a leading manufacturer of golf clubs and related products under the Callaway, Jack Wolfskin, OGIO and TravisMathew brands. The company sells its products through golf and sporting goods retailers as well as mass merchants. Callaway experienced a strong sales rebound in June, with sales rising by 8% compared to June 2019. Still, the overall second quarter operating performance was poor due to COVID-19. Revenue fell 34% to $297 million, while adjusted earnings plummeted 84% to $0.06 per share. Writing for Raymond James, five-star analyst Joseph Altobello notes while earnings reflected meaningful near-term disruption from COVID-19, the results exceeded expectations on the top and bottom lines. Also, recent trends look encouraging, in the analysts opinion. The stock has mostly recovered from a massive plunge earlier in the year, and is up a whopping 283% since March 18. Altobello is enthusiastic about Callaways prospects going forward. The sport of golf has been somewhat insulated from COVID-19 headwinds given the ability of players to easily maintain social distancing. We anticipate further improvement over the balance of the summer, and with retail essentially open for business, the outlook for equipment manufacturers such as Callaway is much more favorable, while apparel trends are improving as well (albeit to a lesser degree), he explained. Accordingly, Altobello rates Callaway an Outperform (i.e Buy) and puts a $22 price target on the stock, which means theres upside potential of 8%. (To watch Altobellos track record, click here) Overall, the company gets a Strong Buy consensus rating from the analyst community with 8 Buy ratings and only 1 Hold. The average price target matches Altobellos. (See Callaway stock analysis on TipRanks) Canada Goose Holdings Inc. (GOOS) Rounding out our list is Canada Goose, which is known for its red, white and blue patch. It manufactures premium outerwear such as parkas, down jackets, rainwear and knitwear. Canada Goose has taken a heavy hit from the COVID-19 pandemic. Sales and earnings per share in the most recent quarter sank 63% and 66%, respectively, though they were basically in line with expectations. Management has taken steps to ease the pain by improving inventory management and realigning its cost structure. In addition, with online sales rising sharply, the company has increased investments to support the demand. Wells Fargo analyst Ike Boruchow weighed in on the initiatives, stating, GOOS can weather the stormLooking ahead, favorable seasonality limits headwinds in 1H and the focus is on improvements in the key holiday quarter. So, where does the company go from here? The Wells Fargo analyst is of the opinion that the brand has staying power, noting that it has bounced back by 69% since March 16. Canada Goose is a heritage brand rooted by the made in Canada identity and family-run origins. This authenticity appeals to a range of customers across the fashion luxury and recreational outdoor spaces, providing a broad addressable market, which we believe remains still largely untapped given the sales base of their much-larger competitors, he said. Whats more, Boruchow believes there are still significant untapped opportunities for growth. Expounding on this, he commented, "When looking at GOOS across the spectrum of other outerwear brands (both mid-tier and luxury) it appears that the brand still has runway for growth as they begin to push ancillary channels, categories and geographies. Based on the above, Boruchow has an Overweight (i.e Buy) rating on GOOS. The price target of US$34.45 (C$45) represents substantial potential returns of 37%. (To watch Boruchows track record, click here) What does the rest of the Street say? The bulls win with an overwhelming majority. 7 Buys and only 1 Hold translate to a Strong Buy consensus rating from the analyst community. The average price target of US$30.37 (C$39.79) is not as bullish as Boruchows, but still offers a significant potential return of 21%. (See Canada Goose stock analysis on TipRanks) Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Read more:
The Week Ahead In Biotech: Focus On Mallinckrodt FDA Decision, Conference Presentations - Yahoo Finance

Global Gaucher Disease Treatment Marketis estimated to surpass 956.2 USD Million mark in 2018 and reach XX USD Million by 2026, at a Compound Annual Growth Rate (CAGR) of XX % during the forecast period 2018-2026 globally.Global Gaucher Disease Treatment Market, By Therapy TypeGaucher disease is a disorder of gene or a hereditary condition in which body fat (lipid) a glucosylceramide gets accumulated into tissue and certain organs, an accumulation is mainly caused by a deficiency of enzyme B-glucocerebrosidase, which then cause complications and is characterized by low blood platelet count, fatigue, bruising, etc. The Gaucher disease is also characterized by the enlargement of the liver and spleen. Sometimes, people may have no disease symptoms and children are more prone to Gaucher disease than adults.

Global Gaucher Disease Treatment Market is driven by rising demand for adequate and well control treatment for the disease. New drug approvals for disease treatment are expected to positively impact global Gaucher disease treatment market in near future. On the contrary, the availability of low patient pool to carry out enough clinical trials is hampering the Global Gaucher Disease Treatment Market.

Global Gaucher Disease Treatment Market has been segmented into disease type, therapy type, distribution channel, and geography. Based on disease type, type 1 gaucher disease, accounted for largest share of the market in 2017, compared to type 2 gaucher disease, and type 3 gaucher disease due to the slight high prevalence over the population. Among the Therapy types, enzyme replacement therapy coupled with recent advancement leading the market segment.

On the basis of region, Global Gaucher disease treatment market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In the year 2018, North America is expected to hold the largest share of the Global Gaucher Disease Treatment Market due to the increasing research activities for drug development. Also, the presence of key market players in the region and their revenue-generating strategies driving the growth of the regional market. European gaucher disease treatment market is expected to remain the second largest market due to increasing awareness programs about gaucher disease treatment.

Maximize Market Research has comprehensively analysed Global Gaucher Disease Treatment Market emphasizing on each and every segment keeping global and regional dynamics in perspective. The driving forces, as well as considerable restraints, have been explained in depth to attain a balanced scenario. The report classifies Global Gaucher disease treatment market into various segments such as disease type, therapy type, distribution channel and regions providing a thorough understanding of the gaucher disease treatment. Ecosystem. Importantly, the report delivers forecasts of the market, giving an insight into the future opportunities that exist in the Global Gaucher Disease Treatment Market.

The objective of the report is to present comprehensive Global Gaucher Disease Treatment Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.

The report also helps in understanding Global Gaucher Disease Treatment Market North America for Asia Pacific dynamics, structure by analyzing the market segments, and project the Global Gaucher Disease Treatment Market North America for Asia Pacific size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Gaucher Disease Treatment Market North America for Asia Pacific make the report investors guide.Scope of the Global Gaucher Disease Treatment Market:

Global Gaucher Disease Treatment Market, By Disease Type:

Type 1 Type2 Type 3Global Gaucher Disease Treatment Market, By Therapy Type:

Enzyme Replacement Therapy (ERT) Substrate Reduction Therapy (SRT)Global Gaucher Disease Treatment Market, By Region:

North America Europe Asia Pacific Middle East & Africa South AmericaKey Players Operating In Global Gaucher Disease Treatment Market:

Pfizer, Inc. Abbott GlaxoSmithKline (GSK) Genzyme Corporation Eli Lilly & Company Aptalis Pharma Actelion Pharmaceuticals Ltd. Shire Human Genetic Therapies, Inc. Enobia Pharma Inc. Greenovation Biopharma BioMarin Pharmaceutical Inc. Zymenex A/S MedPro Rx JCR Pharmaceuticals Co.Ltd

Global Gaucher Disease Treatment Market Request For View Sample Report Page : @https://www.maximizemarketresearch.com/request-sample/11228

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:Name: Vikas GodageOrganization: MAXIMIZE MARKET RESEARCH PVT. LTD.Email: [emailprotected]Website:www.maximizemarketresearch.com

See original here:
Global Gaucher Disease Treatment Market Analysis and Forecast (2019-2026) by Disease Type, by Therapy Type, by Distribution Channel, and by...

Basel, 7 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States (US) Food and Drug Administration (FDA) has approved Gavreto (pralsetinib) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. This indication was approved under the FDAs Accelerated Approval programme, based on data from the phase I/II ARROW study. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Gavreto is a once-daily, oral precision therapy designed to selectively target RET alterations, including fusions and mutations. It is jointly commercialised by Genentech, a wholly owned member of the Roche Group, and Blueprint Medicines in the US and will be commercialised by Roche outside of the US, excluding Greater China*.

The FDA approval of Gavreto for RET fusion-positive non-small cell lung cancer is an important step towards our goal of providing an effective treatment option for every person diagnosed with lung cancer, no matter how rare or hard-to-treat their type of disease, said Levi Garraway, M.D., Ph.D., Roches Chief Medical Officer and Head of Global Product Development. We remain committed to finding personalised treatment options for people with cancer based on specific genomic or molecular alterations, and we look forward to partnering with Blueprint Medicines to further explore the potential of Gavreto across multiple RET-altered tumour types.

RET-activating fusions and mutations are key disease drivers in many cancer types, including NSCLC and medullary thyroid cancer (MTC), and treatment options that selectively target these genetic alterations are limited. In NSCLC, RET fusions represent approximately 1-2% of patients.1 Biomarker testing for these fusions is the most effective way to identify people who are eligible for treatment with Gavreto.

The approval is based on the results from the phase I/II ARROW study, in which Gavreto produced durable clinical responses in people with RET fusion-positive NSCLC with or without prior therapy, and regardless of RET fusion partner or central nervous system involvement.2 Gavreto demonstrated an overall response rate (ORR) of 57% (95% CI: 46%, 68%) and complete response (CR) rate of 5.7% in the 87 people with NSCLC previously treated with platinum-based chemotherapy, and the median duration of response (DoR) was not reached (95% CI: 15.2 months, not reached).2 In the 27 people with treatment-nave NSCLC, the ORR was 70% (95% CI: 50%, 86%), with an 11% CR rate.2 The most common adverse reactions (25%) were fatigue, constipation, musculoskeletal pain and increased blood pressure (hypertension).2

Gavreto is now the sixth FDA-approved medicine in Roches portfolio of treatments for lung cancer. The FDA granted Breakthrough Therapy Designation to Gavreto for the treatment of RET fusion-positive NSCLC that has progressed following platinum-based chemotherapy and for RET mutation-positive MTC that requires systemic treatment and for which there are no acceptable alternative treatments.

The FDA has also granted Priority Review to Gavreto for the treatment of people with advanced or metastatic RET-mutant MTC and RET fusion-positive thyroid cancer, and is expected to make a decision on approval by 28 February 2021. This New Drug Application (NDA) was accepted for review under the FDA's Real-Time Oncology Review (RTOR) pilot programme, which aims to explore a more efficient review process to ensure safe and effective treatments are available to patients as early as possible.

About the ARROW study3ARROW (NCT03037385) is a phase I/II, open-label, first-in-human study designed to evaluate the safety, tolerability and efficacy of Gavreto, administered orally in people with rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC), RET fusion-positive thyroid cancer and other RET-altered solid tumours. The trial consists of two parts: a dose escalation portion, which is complete, and an expansion portion in people treated with 400 mg of Gavreto, once-daily. ARROW is being conducted at multiple sites across the United States, European Union and Asia.

About GavretoGavreto is a once-daily, oral precision therapy designed to selectively target RET alterations, including fusions and mutations, regardless of the tissue of origin. Preclinical data have shown that Gavreto inhibits primary RET fusions and mutations that cause cancer in subsets of patients, as well as secondary RET mutations predicted to drive resistance to treatment. Blueprint Medicines and Roche are also co-developing Gavreto for the treatment of patients with various types of RET-altered thyroid cancers and other solid tumours.

About Roche in lung cancerLung cancer is a major area of focus and investment for Roche, and we are committed to developing new approaches, medicines and tests that can help people with this deadly disease. Our goal is to provide an effective treatment option for every person diagnosed with lung cancer. We currently have six approved medicines to treat certain kinds of lung cancer and more than ten medicines being developed to target the most common genetic drivers of lung cancer or to boost the immune system to combat the disease.About RocheRoche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve peoples lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the worlds largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit http://www.roche.com.

All trademarks used or mentioned in this release are protected by law.* Greater China encompasses Mainland China, Hong Kong, Macau and TaiwanReferences[1] Drilon et al. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol. 2018;15:15167.[2] Blueprint Medicines. Data on file.[3] ClinicalTrials.gov. Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW) [Internet; cited August 2020]. Available from: https://clinicaltrials.gov/ct2/show/NCT03037385.

Roche Group Media RelationsPhone: +41 61 688 8888 / e-mail: media.relations@roche.com

See the rest here:
Roche announces FDA approval of Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer -...

DUBLIN, Sept. 4, 2020 /PRNewswire/ -- The "Global Gene Therapy Market (by Cell Type, Vector Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.

The global gene therapy market is expected to reach US$ 6.42 billion in 2024, witnessing growth at a CAGR of 19.29%, over the period 2020-2024. Growth in the gene therapy market has accrued due to the increasing prevalence of chronic diseases, rising healthcare expenditure, expanding urbanization, growth of gene therapy clinical trials and upsurge in economic growth. The market is anticipated to experience certain trends like rapid adoption of personalized medicine, growing occurrence of genetic disorders, advancements in gene therapy and increasing R&D funding. The growth of the market would be challenged by side effects of gene therapy and ethical and safety concerns and high cost of the treatment.

The global gene therapy market has been segmented on the basis of cell type, vector type, application, end-user and region. Depending on the cell type, the market can be bifurcated into somatic cell gene therapy and germ cell gene therapy. According to the vector type, the global gene therapy market can be categorized into retrovirus & gammaretrovirus, adeno-associated viruses (AAV), lentivirus, adenovirus, modified herpes simplex virus and non-viral plasmid vector. Whereas, on the basis of application, the market can be split into oncological disorders, neurological disorders, infectious diseases, cardiovascular diseases, rare diseases and others. Further, in terms of end-user, the global gene therapy market can broadly be segmented into hospitals, specialty treatment centers and other end-users.

The fastest-growing regional market is North America due to the rising incidence of cancer and other target diseases, increasing favorable reimbursement scenario in the region and improvements in healthcare infrastructure. Further, the sudden outbreak of COVID-19 is causing an adverse disruption on the overall economy and society, affecting the rate of gene therapy procedures and clinical trials, which is expected to negatively impact the growth of the global gene therapy market during the forecasted period.

Scope of the report:

Key Target Audience:

Key Topics Covered:

1. Market Overview1.1 Introduction1.2 Diseases Treated by Gene Therapy1.3 Process of Gene Therapy1.4 Types of Gene Therapy1.5 Application Areas for Gene Therapy1.6 Gene Therapy Techniques1.7 Advantages & Disadvantages of Gene Therapy

2. Impact of COVID-192.1 Economic Impact2.2 Decline in Global GDP2.3 Decline in Industrial Production2.4 Impact on Gene Therapy2.5 Impact on Clinical Trials of Gene Therapy

3. Global Market Analysis3.1 Global Gene Therapy Market by Value3.2 Global Gene Therapy Market Forecast by Value3.3 Global Gene Therapy Market by Cell Type3.4 Global Gene Therapy Market by Vector Type3.5 Global Gene Therapy Market by Application3.6 Global Gene Therapy Market by End-User3.7 Global Gene Therapy Market by Region

4. Regional Market Analysis4.1 North America4.2 Europe4.3 Asia Pacific4.4 RoW

5. Market Dynamics5.1 Growth Drivers5.1.1 Increasing Prevalence of Chronic Diseases5.1.2 Rising Healthcare Expenditure5.1.3 Expanding Urbanization5.1.4 Growth of Gene Therapy Clinical Trials5.1.5 Upsurge in Economic Growth5.2 Key Trends and Developments5.2.1 Rapid Adoption of Personalized Medicines5.2.2 Growing Occurrence of Genetic Disorders5.2.3 Advancements in Gene Therapy5.2.4 Increasing R&D Funding5.3 Challenges5.3.1 Side Effects of Gene Therapy5.3.2 Ethical and Safety Concerns5.3.3 High Cost of Treatment

6. Competitive Landscape6.1 Global Market6.1.1 Revenue Comparison of Key Players6.1.2 Market Capitalization Comparison of Key Players6.1.3 R&D Comparison of Key Players

7. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/7ewray

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and MarketsLaura Wood, Senior Managerpress@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716

Read more:
Global Gene Therapy Market is Forecast to Reach US$ 6.42 billion in 2024, Witnessing Growth at a CAGR of 19.29% Over 2020-2024 - WFMZ Allentown

The success of the approved gene therapies has led to an upward surge in the interest of biopharmaceutical developers in this field, resulting in a significant boost in clinical research initiatives and several high value acquisitions

Roots Analysis has announced the addition of Gene Therapy Market (3rd Edition), 2019-2030 report to its list of offerings.

Encouraging clinical results across various metabolic, hematological and ophthalmic disorders have inspired research groups across the world to focus their efforts on the development of novel gene editing therapies. In fact, the gene therapy pipeline has evolved significantly over the past few years, with three products being approved in 2019 alone; namely Beperminogene perplasmid (AnGes), ZOLGENSMA (AveXis) and ZYNTEGLO (bluebird bio). Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials that are anticipated to enter the market over the next 5-10 years.

To order this 550+ page report, which features 190+ figures and 355+ tables, please visit this link

Around 470 gene therapies are currently under developmentNearly 45% of pipeline drugs are in the clinical phase, while rest are in the preclinical / discovery stage. Gene augmented therapies presently represent 66% of the total number of such interventions that are in the pipeline. It is worth mentioning that majority of such product candidates are being developed as in vivo gene therapies.

More than 30% of clinical stage pipeline therapies are being designed for treating oncological disordersConsidering the overall pipeline, over 20% of product candidates are being developed to treat various types of cancers, followed by those intended for the treatment of metabolic (15%) and ophthalmic disorders (12%). It is also worth highlighting that adenovirus vectors are presently the preferred vehicles used for the delivery of anticancer gene therapies.

Over 60% of gene therapy developers are based in North AmericaOf the 110 companies developing gene therapies in the abovementioned region, 64 are start-ups, 26 are mid-sized players, while 18 are large and very large companies. Further, within this region, most of the developers are based in the US, which has emerged as a key R&D hub for advanced therapeutic products.

More than 31,000 patents have been filed / published related to gene therapies, since 2016Of these, 17% of patent applications / patents were related to gene editing therapies, while the remaining were associated with gene therapies. Leading assignees, in terms of the size of intellectual property portfolio, include (industry players) Genentech, GSK, Sangamo Therapeutics, Bayer and Novartis, (non-industry players) University of California, Massachusetts Institute of Technology, Harvard College, Stanford University and University of Pennsylvania.

USD 16.5 billion has been invested by both private and public investors, since 2014Around USD 3.3 billion was raised through venture capital financing, representing 20% of the total capital raised by industry players till June 2019. Further, there have been 28 IPOs, accounting for more than USD 2.2 billion in financing of gene therapy related initiatives. These companies have also raised significant capital in secondary offerings.

30+ mergers / acquisitions have been established between 2014 and 2019Examples of high value acquisitions reported in recent past include the acquisition of AveXis by Novartis (2018, USD 8,700 million) and Bioverativ by Sanofi (2018, USD 11,600 million).

North America and Europe are anticipated to capture over 85% of market share by 2030With a promising development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of over 40% during the next decade. In addition to North America and Europe, the market in China / broader Asia Pacific region is also anticipated to grow at a relatively faster rate.

To request a sample copy / brochure of this report, please visit this link

The USD 10 billion (by 2030) financial opportunity within the gene therapy market has been analyzed across the following segments:

The report features inputs from eminent industry stakeholders, according to whom gene therapies are likely to be the most promising treatment options for genetic disorders. The report includes detailed transcripts of discussions held with the following experts:

The research covers brief profiles, featuring an overview of the therapy, current development status and clinical results. Each profile includes information on therapeutic indication, targeted gene, route of administration, special designations, mechanism of action, dosage, patent portfolio, technology portfolio, clinical trials and recent developments (if available).

For additional details, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html

or email [emailprotected]

Contact:Gaurav Chaudhary+1 (415) 800 3415+44 (122) 391 1091[emailprotected]

Read more:
Gene Therapy Market is projected to be worth USD 10 Billion by 2030, growing at an annualized rate of over 40% - Scientect